Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK and safety study of doravirine with 2 NRTIs in HIV-1 infection (pediatric)
2019-003955-13Phase 2
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of doravirine in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoint: Doravirine AUC0-24hr at steady state with 2 NRTIs.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-003955-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003955-13.